Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 2-3/2018

09.06.2018

Stress, inflammation, and eicosanoids: an emerging perspective

verfasst von: Sujanitha Umamaheswaran, Santosh K. Dasari, Peiying Yang, Susan K. Lutgendorf, Anil K. Sood

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2-3/2018

Einloggen, um Zugang zu erhalten

Abstract

Clinical and experimental studies support the notion that adrenergic stimulation and chronic stress affect inflammation, metabolism, and tumor growth. Eicosanoids are also known to heavily influence inflammation while regulating certain stress responses. However, additional work is needed to understand the full extent of interactions between the stress-related pathways and eicosanoids. Here, we review the potential influences that stress, inflammation, and metabolic pathways have on each other, in the context of eicosanoids. Understanding the intricacies of such interactions could provide insights on how systemic metabolic effects mediated by the stress pathways can be translated into therapies for cancer and other diseases.
Literatur
1.
Antoni, M. H., Lutgendorf, S. K., Cole, S. W., Dhabhar, F. S., Sephton, S. E., McDonald, P. G., Stefanek, M., & Sood, A. K. (2006). The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nature Reviews. Cancer, 6(3), 240–248.PubMedPubMedCentralCrossRef
2.
Glaser, R., & Kiecolt-Glaser, J. K. (2005). Stress-induced immune dysfunction: implications for health. Nature Reviews. Immunology, 5(3), 243–251.PubMedCrossRef
3.
Charmandari, E., Tsigos, C., & Chrousos, G. (2005). Endocrinology of the stress response. Annual Review of Physiology, 67, 259–284.PubMedCrossRef
4.
McEwen, B. S. (2002). Sex, stress and the hippocampus: allostasis, allostatic load and the aging process. Neurobiology of Aging, 23(5), 921–939.PubMedCrossRef
5.
Penninx, B. W., et al. (1998). Chronically depressed mood and cancer risk in older persons. Journal of the National Cancer Institute, 90(24), 1888–1893.PubMedCrossRef
6.
Duijts, S. F., Zeegers, M. P., & Borne, B. V. (2003). The association between stressful life events and breast cancer risk: a meta-analysis. International Journal of Cancer, 107(6), 1023–1029.PubMedCrossRef
7.
Bleiker, E. M., et al. (2008). Personality factors and breast cancer risk: a 13-year follow-up. Journal of the National Cancer Institute, 100(3), 213–218.PubMedCrossRef
8.
Price, M. A., Tennant, C. C., Smith, R. C., Butow, P. N., Kennedy, S. J., Kossoff, M. B., & Dunn, S. M. (2001). The role of psychosocial factors in the development of breast carcinoma: part I. The cancer prone personality. Cancer, 91(4), 679–685.PubMedCrossRef
9.
Chida, Y., Hamer, M., Wardle, J., & Steptoe, A. (2008). Do stress-related psychosocial factors contribute to cancer incidence and survival? Nature Clinical Practice. Oncology, 5(8), 466–475.PubMedCrossRef
10.
Selye, H. (1998). A syndrome produced by diverse nocuous agents. 1936. The Journal of Neuropsychiatry and Clinical Neurosciences, 10(2), 230–231.PubMedCrossRef
11.
Reiche, E. M., Nunes, S. O., & Morimoto, H. K. (2004). Stress, depression, the immune system, and cancer. The Lancet Oncology, 5(10), 617–625.PubMedCrossRef
12.
Cole, S. W., Nagaraja, A. S., Lutgendorf, S. K., Green, P. A., & Sood, A. K. (2015). Sympathetic nervous system regulation of the tumour microenvironment. Nature Reviews. Cancer, 15(9), 563–572.PubMedPubMedCentralCrossRef
13.
Hassan, S., Karpova, Y., Baiz, D., Yancey, D., Pullikuth, A., Flores, A., Register, T., Cline, J. M., D’Agostino R Jr, Danial, N., Datta, S. R., & Kulik, G. (2013). Behavioral stress accelerates prostate cancer development in mice. The Journal of Clinical Investigation, 123(2), 874–886.PubMedPubMedCentral
14.
Kruk, J., & Aboul-Enein, H. Y. (2004). Psychological stress and the risk of breast cancer: a case-control study. Cancer Detection and Prevention, 28(6), 399–408.PubMedCrossRef
15.
Lutgendorf, S. K., de Geest, K., Bender, D., Ahmed, A., Goodheart, M. J., Dahmoush, L., Zimmerman, M. B., Penedo, F. J., Lucci III, J. A., Ganjei-Azar, P., Thaker, P. H., Mendez, L., Lubaroff, D. M., Slavich, G. M., Cole, S. W., & Sood, A. K. (2012). Social influences on clinical outcomes of patients with ovarian cancer. Journal of Clinical Oncology, 30(23), 2885–2890.PubMedPubMedCentralCrossRef
16.
Ramirez, A. J., Craig, T. K., Watson, J. P., Fentiman, I. S., North, W. R., & Rubens, R. D. (1989). Stress and relapse of breast cancer. BMJ, 298(6669), 291–293.PubMedPubMedCentralCrossRef
17.
Thaker, P. H., Han, L. Y., Kamat, A. A., Arevalo, J. M., Takahashi, R., Lu, C., Jennings, N. B., Armaiz-Pena, G., Bankson, J. A., Ravoori, M., Merritt, W. M., Lin, Y. G., Mangala, L. S., Kim, T. J., Coleman, R. L., Landen, C. N., Li, Y., Felix, E., Sanguino, A. M., Newman, R. A., Lloyd, M., Gershenson, D. M., Kundra, V., Lopez-Berestein, G., Lutgendorf, S. K., Cole, S. W., & Sood, A. K. (2006). Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nature Medicine, 12(8), 939–944.PubMedCrossRef
18.
Wang, H. M., Liao, Z. X., Komaki, R., Welsh, J. W., O’Reilly, M. S., Chang, J. Y., Zhuang, Y., Levy, L. B., Lu, C., & Gomez, D. R. (2013). Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Annals of Oncology, 24(5), 1312–1319.PubMedPubMedCentralCrossRef
19.
Nagaraja, A. S., Dorniak, P. L., Sadaoui, N. C., Kang, Y., Lin, T., Armaiz-Pena, G., Wu, S. Y., Rupaimoole, R., Allen, J. K., Gharpure, K. M., Pradeep, S., Zand, B., Previs, R. A., Hansen, J. M., Ivan, C., Rodriguez-Aguayo, C., Yang, P., Lopez-Berestein, G., Lutgendorf, S. K., Cole, S. W., & Sood, A. K. (2016). Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene, 35(18), 2390–2397.PubMedCrossRef
20.
Sanders, V. M., & Straub, R. H. (2002). Norepinephrine, the beta-adrenergic receptor, and immunity. Brain, Behavior, and Immunity, 16(4), 290–332.PubMedCrossRef
21.
Jean, D., & Bar-Eli, M. (2000). Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. Molecular and Cellular Biochemistry, 212(1–2), 19–28.PubMedCrossRef
22.
Sood, A. K., Bhatty, R., Kamat, A. A., Landen, C. N., Han, L., Thaker, P. H., Li, Y., Gershenson, D. M., Lutgendorf, S., & Cole, S. W. (2006). Stress hormone-mediated invasion of ovarian cancer cells. Clinical Cancer Research, 12(2), 369–375.PubMedPubMedCentralCrossRef
23.
Yang, E. V., Sood, A. K., Chen, M., Li, Y., Eubank, T. D., Marsh, C. B., Jewell, S., Flavahan, N. A., Morrison, C., Yeh, P. E., Lemeshow, S., & Glaser, R. (2006). Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Research, 66(21), 10357–10364.PubMedCrossRef
24.
Landen Jr., C. N., et al. (2007). Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Research, 67(21), 10389–10396.PubMedCrossRef
25.
Li, W., Yu, C. P., Xia, J. T., Zhang, L., Weng, G. X., Zheng, H. Q., Kong, Q. L., Hu, L. J., Zeng, M. S., Zeng, Y. X., Li, M., Li, J., & Song, L. B. (2009). Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clinical Cancer Research, 15(4), 1393–1399.PubMedCrossRef
26.
Hansen-Petrik, M. B., McEntee, M., Jull, B., Shi, H., Zemel, M. B., & Whelan, J. (2002). Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(min/+) mice. Cancer Research, 62(2), 403–408.PubMed
27.
Yan, M., Myung, S. J., Fink, S. P., Lawrence, E., Lutterbaugh, J., Yang, P., Zhou, X., Liu, D., Rerko, R. M., Willis, J., Dawson, D., Tai, H. H., Barnholtz-Sloan, J. S., Newman, R. A., Bertagnolli, M. M., & Markowitz, S. D. (2009). 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proceedings of the National Academy of Sciences of the United States of America, 106(23), 9409–9413.PubMedPubMedCentralCrossRef
28.
29.
Colby, J. K., et al. (2008). Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia, 10(8), 782–796.PubMedPubMedCentralCrossRef
30.
Lewis, R. A., Austen, K. F., & Soberman, R. J. (1990). Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. The New England Journal of Medicine, 323(10), 645–655.PubMedCrossRef
31.
Agarwal, S., Reddy, G. V., & Reddanna, P. (2009). Eicosanoids in inflammation and cancer: the role of COX-2. Expert Review of Clinical Immunology, 5(2), 145–165.PubMedCrossRef
32.
Harizi, H., Corcuff, J. B., & Gualde, N. (2008). Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends in Molecular Medicine, 14(10), 461–469.PubMedCrossRef
33.
Ruder, E. H., Laiyemo, A. O., Graubard, B. I., Hollenbeck, A. R., Schatzkin, A., & Cross, A. J. (2011). Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. The American Journal of Gastroenterology, 106(7), 1340–1350.PubMedPubMedCentralCrossRef
34.
Kuo, C. N., Pan, J. J., Huang, Y. W., Tsai, H. J., & Chang, W. C. (2018). Association between nonsteroidal anti-inflammatory drugs and colorectal cancer: a population-based case-control study. Cancer Epidemiology, Biomarkers & Prevention.
35.
Harris, R. E. (2009). Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology, 17(2), 55–67.PubMedCrossRef
36.
Gurpinar, E., Grizzle, W. E., & Piazza, G. A. (2014). NSAIDs inhibit tumorigenesis, but how? Clinical Cancer Research, 20(5), 1104–1113.PubMedCrossRef
37.
Narumiya, S. (2007). Physiology and pathophysiology of prostanoid receptors. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 83(9–10), 296–319.PubMedPubMedCentralCrossRef
38.
Brown, J. R., & DuBois, R. N. (2005). COX-2: a molecular target for colorectal cancer prevention. Journal of Clinical Oncology, 23(12), 2840–2855.PubMedCrossRef
39.
Sebaldt, R. J., Sheller, J. R., Oates, J. A., Roberts, L. J., & FitzGerald, G. A. (1990). Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proceedings of the National Academy of Sciences of the United States of America, 87(18), 6974–6978.PubMedPubMedCentralCrossRef
40.
Masferrer, J. L., Seibert, K., Zweifel, B., & Needleman, P. (1992). Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proceedings of the National Academy of Sciences of the United States of America, 89(9), 3917–3921.PubMedPubMedCentralCrossRef
41.
Brenner, T., Boneh, A., Shohami, E., Abramsky, O., & Weidenfeld, J. (1992). Glucocorticoid regulation of eicosanoid production by glial cells under basal and stimulated conditions. Journal of Neuroimmunology, 40(2–3), 273–279.PubMedCrossRef
42.
Fu, J. Y., Masferrer, J. L., Seibert, K., Raz, A., & Needleman, P. (1990). The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. The Journal of Biological Chemistry, 265(28), 16737–16740.PubMed
43.
Chatzopoulou, A., Heijmans, J. P. M., Burgerhout, E., Oskam, N., Spaink, H. P., Meijer, A. H., & Schaaf, M. J. M. (2016). Glucocorticoid-induced attenuation of the inflammatory response in zebrafish. Endocrinology, 157(7), 2772–2784.PubMedCrossRef
44.
Tahir, A., Bileck, A., Muqaku, B., Niederstaetter, L., Kreutz, D., Mayer, R. L., Wolrab, D., Meier, S. M., Slany, A., & Gerner, C. (2017). Combined proteome and eicosanoid profiling approach for revealing implications of human fibroblasts in chronic inflammation. Analytical Chemistry, 89(3), 1945–1954.PubMedCrossRef
45.
Furuyashiki, T., & Narumiya, S. (2011). Stress responses: the contribution of prostaglandin E(2) and its receptors. Nature Reviews. Endocrinology, 7(3), 163–175.PubMedCrossRef
46.
Elander, L., Engstrom, L., Ruud, J., Mackerlova, L., Jakobsson, P. J., Engblom, D., Nilsberth, C., & Blomqvist, A. (2009). Inducible prostaglandin E2 synthesis interacts in a temporally supplementary sequence with constitutive prostaglandin-synthesizing enzymes in creating the hypothalamic-pituitary-adrenal axis response to immune challenge. The Journal of Neuroscience, 29(5), 1404–1413.PubMedCrossRef
47.
Elmquist, J. K., Breder, C. D., Sherin, J. E., Scammell, T. E., Hickey, W. F., Dewitt, D., & Saper, C. B. (1997). Intravenous lipopolysaccharide induces cyclooxygenase 2-like immunoreactivity in rat brain perivascular microglia and meningeal macrophages. The Journal of Comparative Neurology, 381(2), 119–129.PubMedCrossRef
48.
Elander, L., Ruud, J., Korotkova, M., Jakobsson, P. J., & Blomqvist, A. (2010). Cyclooxygenase-1 mediates the immediate corticosterone response to peripheral immune challenge induced by lipopolysaccharide. Neuroscience Letters, 470(1), 10–12.PubMedCrossRef
49.
Garcia-Bueno, B., Serrats, J., & Sawchenko, P. E. (2009). Cerebrovascular cyclooxygenase-1 expression, regulation, and role in hypothalamic-pituitary-adrenal axis activation by inflammatory stimuli. The Journal of Neuroscience, 29(41), 12970–12981.PubMedCrossRef
50.
Turnbull, A. V., & Rivier, C. L. (1999). Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiological Reviews, 79(1), 1–71.PubMedCrossRef
51.
Matsuoka, Y., Furuyashiki, T., Bito, H., Ushikubi, F., Tanaka, Y., Kobayashi, T., Muro, S., Satoh, N., Kayahara, T., Higashi, M., Mizoguchi, A., Shichi, H., Fukuda, Y., Nakao, K., & Narumiya, S. (2003). Impaired adrenocorticotropic hormone response to bacterial endotoxin in mice deficient in prostaglandin E receptor EP1 and EP3 subtypes. Proceedings of the National Academy of Sciences of the United States of America, 100(7), 4132–4137.PubMedPubMedCentralCrossRef
52.
Ericsson, A., Arias, C., & Sawchenko, P. E. (1997). Evidence for an intramedullary prostaglandin-dependent mechanism in the activation of stress-related neuroendocrine circuitry by intravenous interleukin-1. The Journal of Neuroscience, 17(18), 7166–7179.PubMedCrossRef
53.
Matsuoka, Y., Furuyashiki, T., Yamada, K., Nagai, T., Bito, H., Tanaka, Y., Kitaoka, S., Ushikubi, F., Nabeshima, T., & Narumiya, S. (2005). Prostaglandin E receptor EP1 controls impulsive behavior under stress. Proceedings of the National Academy of Sciences of the United States of America, 102(44), 16066–16071.PubMedPubMedCentralCrossRef
54.
Garcia-Bueno, B., et al. (2008). Stress mediators regulate brain prostaglandin synthesis and peroxisome proliferator-activated receptor-gamma activation after stress in rats. Endocrinology, 149(4), 1969–1978.PubMedCrossRef
55.
Yamagata, K., Andreasson, K. I., Kaufmann, W. E., Barnes, C. A., & Worley, P. F. (1993). Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron, 11(2), 371–386.PubMedCrossRef
56.
McLemore, T. L., et al. (1988). Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Research, 48(11), 3140–3147.PubMed
57.
Rigas, B., Goldman, I. S., & Levine, L. (1993). Altered eicosanoid levels in human colon cancer. The Journal of Laboratory and Clinical Medicine, 122(5), 518–523.PubMed
58.
Wang, D., & Dubois, R. N. (2004). Cyclooxygenase-2: a potential target in breast cancer. Seminars in Oncology, 31(1 Suppl 3), 64–73.PubMedCrossRef
59.
Allen, J. K., Armaiz-Pena, G. N., Nagaraja, A. S., Sadaoui, N. C., Ortiz, T., Dood, R., Ozcan, M., Herder, D. M., Haemerrle, M., Gharpure, K. M., Rupaimoole, R., Previs, R., Wu, S. Y., Pradeep, S., Xu, X., Dong Han, H., Zand, B., Dalton, H. J., Taylor, M., Hu, W., Bottsford-Miller, J., Moreno-Smith, M., Kang, Y., Mangala, L. S., Rodriguez-Aguayo, C., Sehgal, V., Spaeth, E. L., Ram, P. T., Wong, S. T. C., Marini, F. C., Lopez-Berestein, G., Cole, S. W., Lutgendorf, S. K., diBiasi, M., & Sood, A. K. (2018). Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction. In Cancer Res (p. canres.1701.2016).
60.
Renz, B. W., et al. (2018). β2 Adrenergic-neurotrophin feedforward loop promotes pancreatic cancer. Cancer Cell, 33(1), 75–90 e7.PubMedCrossRef
61.
Sloan, E. K., Capitanio, J. P., & Cole, S. W. (2008). Stress-induced remodeling of lymphoid innervation. Brain, Behavior, and Immunity, 22(1), 15–21.PubMedCrossRef
62.
Gosain, A., Jones, S. B., Shankar, R., Gamelli, R. L., & DiPietro, L. A. (2006). Norepinephrine modulates the inflammatory and proliferative phases of wound healing. The Journal of Trauma, 60(4), 736–744.PubMedCrossRef
63.
Sivamani, R. K., Pullar, C. E., Manabat-Hidalgo, C. G., Rocke, D. M., Carlsen, R. C., Greenhalgh, D. G., & Isseroff, R. R. (2009). Stress-mediated increases in systemic and local epinephrine impair skin wound healing: potential new indication for beta blockers. PLoS Medicine, 6(1), e12.PubMedCrossRef
64.
Felten, D. L., et al. (1985). Noradrenergic and peptidergic innervation of lymphoid tissue. Journal of Immunology, 135(2 Suppl), 755s–765s.
65.
Felten, S. Y., & Olschowka, J. (1987). Noradrenergic sympathetic innervation of the spleen: II. Tyrosine hydroxylase (TH)-positive nerve terminals form synapticlike contacts on lymphocytes in the splenic white pulp. Journal of Neuroscience Research, 18(1), 37–48.PubMedCrossRef
66.
Maestroni, G. J., & Mazzola, P. (2003). Langerhans cells beta 2-adrenoceptors: role in migration, cytokine production, Th priming and contact hypersensitivity. Journal of Neuroimmunology, 144(1–2), 91–99.PubMedCrossRef
67.
Saint-Mezard, P., Chavagnac, C., Bosset, S., Ionescu, M., Peyron, E., Kaiserlian, D., Nicolas, J. F., & Berard, F. (2003). Psychological stress exerts an adjuvant effect on skin dendritic cell functions in vivo. Journal of Immunology, 171(8), 4073–4080.CrossRef
68.
Seiffert, K., Hosoi, J., Torii, H., Ozawa, H., Ding, W., Campton, K., Wagner, J. A., & Granstein, R. D. (2002). Catecholamines inhibit the antigen-presenting capability of epidermal Langerhans cells. Journal of Immunology, 168(12), 6128–6135.CrossRef
69.
Manni, M., Granstein, R. D., & Maestroni, G. (2011). β2-Adrenergic agonists bias TLR-2 and NOD2 activated dendritic cells towards inducing an IL-17 immune response. Cytokine, 55(3), 380–386.PubMedPubMedCentralCrossRef
70.
Yanagawa, Y., Matsumoto, M., & Togashi, H. (2011). Adrenoceptor-mediated enhancement of interleukin-33 production by dendritic cells. Brain, Behavior, and Immunity, 25(7), 1427–1433.PubMedCrossRef
71.
Alaniz, R. C., Thomas, S. A., Perez-Melgosa, M., Mueller, K., Farr, A. G., Palmiter, R. D., & Wilson, C. B. (1999). Dopamine beta-hydroxylase deficiency impairs cellular immunity. Proceedings of the National Academy of Sciences of the United States of America, 96(5), 2274–2278.PubMedPubMedCentralCrossRef
72.
Swanson, M. A., Lee, W. T., & Sanders, V. M. (2001). IFN-gamma production by Th1 cells generated from naive CD4+ T cells exposed to norepinephrine. Journal of Immunology, 166(1), 232–240.CrossRef
73.
Guereschi, M. G., Araujo, L. P., Maricato, J. T., Takenaka, M. C., Nascimento, V. M., Vivanco, B. C., Reis, V. O., Keller, A. C., Brum, P. C., & Basso, A. S. (2013). Beta2-adrenergic receptor signaling in CD4+ Foxp3+ regulatory T cells enhances their suppressive function in a PKA-dependent manner. European Journal of Immunology, 43(4), 1001–1012.PubMedCrossRef
74.
Vida, G., et al. (2011). β2-Adrenoreceptors of regulatory lymphocytes are essential for vagal neuromodulation of the innate immune system. The FASEB Journal, 25(12), 4476–4485.PubMedPubMedCentralCrossRef
75.
Benschop, R. J., Jacobs, R., Sommer, B., Schürmeyer, T. H., Raab, J. R., Schmidt, R. E., & Schedlowski, M. (1996). Modulation of the immunologic response to acute stress in humans by beta-blockade or benzodiazepines. The FASEB Journal, 10(4), 517–524.PubMedCrossRef
76.
Mathews, P. M., et al. (1983). Enhancement of natural cytotoxicity by beta-endorphin. Journal of Immunology, 130(4), 1658–1662.
77.
Deng, J., Muthu, K., Gamelli, R., Shankar, R., & Jones, S. B. (2004). Adrenergic modulation of splenic macrophage cytokine release in polymicrobial sepsis. American Journal of Physiology. Cell Physiology, 287(3), C730–C736.PubMedCrossRef
78.
Elenkov, I. J., et al. (1996). Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proceedings of the Association of American Physicians, 108(5), 374–381.PubMed
79.
Hetier, E., Ayala, J., Bousseau, A., & Prochiantz, A. (1991). Modulation of interleukin-1 and tumor necrosis factor expression by beta-adrenergic agonists in mouse ameboid microglial cells. Experimental Brain Research, 86(2), 407–413.PubMedCrossRef
80.
Panina-Bordignon, P., Mazzeo, D., Lucia, P. D., D’Ambrosio, D., Lang, R., Fabbri, L., Self, C., & Sinigaglia, F. (1997). Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. The Journal of Clinical Investigation, 100(6), 1513–1519.PubMedPubMedCentralCrossRef
81.
Heijnen, C. J., van der Voort, C. R., Wulffraat, N., van der Net, J., Kuis, W., & Kavelaars, A. (1996). Functional alpha 1-adrenergic receptors on leukocytes of patients with polyarticular juvenile rheumatoid arthritis. Journal of Neuroimmunology, 71(1–2), 223–226.PubMedCrossRef
82.
Spengler, R. N., et al. (1990). Stimulation of alpha-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. Journal of Immunology, 145(5), 1430–1434.
83.
Szelenyi, J., Kiss, J. P., & Vizi, E. S. (2000). Differential involvement of sympathetic nervous system and immune system in the modulation of TNF-alpha production by alpha2- and beta-adrenoceptors in mice. Journal of Neuroimmunology, 103(1), 34–40.PubMedCrossRef
84.
Madden, K. S., Szpunar, M. J., & Brown, E. B. (2011). Beta-Adrenergic receptors (beta-AR) regulate VEGF and IL-6 production by divergent pathways in high beta-AR-expressing breast cancer cell lines. Breast Cancer Research and Treatment, 130(3), 747–758.PubMedPubMedCentralCrossRef
85.
Sloan, E. K., Priceman, S. J., Cox, B. F., Yu, S., Pimentel, M. A., Tangkanangnukul, V., Arevalo, J. M. G., Morizono, K., Karanikolas, B. D. W., Wu, L., Sood, A. K., & Cole, S. W. (2010). The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Research, 70(18), 7042–7052.PubMedPubMedCentralCrossRef
86.
Waight, J. D., Netherby, C., Hensen, M. L., Miller, A., Hu, Q., Liu, S., Bogner, P. N., Farren, M. R., Lee, K. P., Liu, K., & Abrams, S. I. (2013). Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. The Journal of Clinical Investigation, 123(10), 4464–4478.PubMedPubMedCentralCrossRef
87.
Gabrilovich, D. I., & Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews. Immunology, 9(3), 162–174.PubMedPubMedCentralCrossRef
88.
Ostrand-Rosenberg, S., Sinha, P., Beury, D. W., & Clements, V. K. (2012). Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Seminars in Cancer Biology, 22(4), 275–281.PubMedPubMedCentralCrossRef
89.
Jin, J., Wang, X., Wang, Q., Guo, X., Cao, J., Zhang, X., Zhu, T., Zhang, D., Wang, W., Wang, J., Shen, B., Gao, X., Shi, Y., & Zhang, J. (2013). Chronic psychological stress induces the accumulation of myeloid-derived suppressor cells in mice. PLoS One, 8(9), e74497.PubMedPubMedCentralCrossRef
90.
Ben-Eliyahu, S., et al. (1999). Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. International Journal of Cancer, 80(6), 880–888.PubMedCrossRef
91.
Benish, M., Bartal, I., Goldfarb, Y., Levi, B., Avraham, R., Raz, A., & Ben-Eliyahu, S. (2008). Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Annals of Surgical Oncology, 15(7), 2042–2052.PubMedCrossRef
92.
Shaashua, L., Shabat-Simon, M., Haldar, R., Matzner, P., Zmora, O., Shabtai, M., Sharon, E., Allweis, T., Barshack, I., Hayman, L., Arevalo, J., Ma, J., Horowitz, M., Cole, S., & Ben-Eliyahu, S. (2017). Perioperative COX-2 and beta-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial. Clinical Cancer Research, 23(16), 4651–4661.PubMedPubMedCentralCrossRef
93.
Noonan, D. M., de Lerma Barbaro, A., Vannini, N., Mortara, L., & Albini, A. (2008). Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Reviews, 27(1), 31–40.PubMedCrossRef
94.
Sheibanie, A. F., Yen, J. H., Khayrullina, T., Emig, F., Zhang, M., Tuma, R., & Ganea, D. (2007). The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23->IL-17 axis. Journal of Immunology, 178(12), 8138–8147.CrossRef
95.
Boniface, K., Bak-Jensen, K. S., Li, Y., Blumenschein, W. M., McGeachy, M. J., McClanahan, T. K., McKenzie, B. S., Kastelein, R. A., Cua, D. J., & de Waal Malefyt, R. (2009). Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. The Journal of Experimental Medicine, 206(3), 535–548.PubMedPubMedCentralCrossRef
96.
Chizzolini, C., Chicheportiche, R., Alvarez, M., de Rham, C., Roux-Lombard, P., Ferrari-Lacraz, S., & Dayer, J. M. (2008). Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood, 112(9), 3696–3703.PubMedPubMedCentralCrossRef
97.
Prescott, S. M., & Fitzpatrick, F. A. (2000). Cyclooxygenase-2 and carcinogenesis. Biochimica et Biophysica Acta, 1470(2), M69–M78.PubMed
98.
Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., & Taketo, M. M. (1996). Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87(5), 803–809.PubMedCrossRef
99.
Obermajer, N., Wong, J. L., Edwards, R. P., Odunsi, K., Moysich, K., & Kalinski, P. (2012). PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunological Investigations, 41(6–7), 635–657.PubMedCrossRef
100.
Huang, Y., Lichtenberger, L. M., Taylor, M., Bottsford-Miller, J. N., Haemmerle, M., Wagner, M. J., Lyons, Y., Pradeep, S., Hu, W., Previs, R. A., Hansen, J. M., Fang, D., Dorniak, P. L., Filant, J., Dial, E. J., Shen, F., Hatakeyama, H., & Sood, A. K. (2016). Antitumor and antiangiogenic effects of aspirin-PC in ovarian cancer. Molecular Cancer Therapeutics, 15(12), 2894–2904.PubMedPubMedCentralCrossRef
101.
Brencicova, E., Jagger, A. L., Evans, H. G., Georgouli, M., Laios, A., Attard Montalto, S., Mehra, G., Spencer, J., Ahmed, A. A., Raju-Kankipati, S., Taams, L. S., & Diebold, S. S. (2017). Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma. PLoS One, 12(4), e0175712.PubMedPubMedCentralCrossRef
102.
Yao, C., Sakata, D., Esaki, Y., Li, Y., Matsuoka, T., Kuroiwa, K., Sugimoto, Y., & Narumiya, S. (2009). Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nature Medicine, 15(6), 633–640.PubMedCrossRef
103.
Bomalaski, J. S., Dundee, D., Brophy, L., & Clark, M. A. (1990). Leukotriene B4 modulates phospholipid methylation and chemotaxis in human polymorphonuclear leukocytes. Journal of Leukocyte Biology, 47(1), 1–12.PubMedCrossRef
104.
Haribabu, B., Verghese, M. W., Steeber, D. A., Sellars, D. D., Bock, C. B., & Snyderman, R. (2000). Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. The Journal of Experimental Medicine, 192(3), 433–438.PubMedPubMedCentralCrossRef
105.
Islam, S. A., Thomas, S. Y., Hess, C., Medoff, B. D., Means, T. K., Brander, C., Lilly, C. M., Tager, A. M., & Luster, A. D. (2006). The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. Blood, 107(2), 444–453.PubMedPubMedCentralCrossRef
106.
Woo, C. H., You, H. J., Cho, S. H., Eom, Y. W., Chun, J. S., Yoo, Y. J., & Kim, J. H. (2002). Leukotriene B(4) stimulates Rac-ERK cascade to generate reactive oxygen species that mediates chemotaxis. The Journal of Biological Chemistry, 277(10), 8572–8578.PubMedCrossRef
107.
Henderson Jr., W. R., et al. (1996). The importance of leukotrienes in airway inflammation in a mouse model of asthma. The Journal of Experimental Medicine, 184(4), 1483–1494.PubMedCrossRef
108.
Park, J., Park, S. Y., & Kim, J. H. (2016). Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade. Biochimica et Biophysica Acta, 1863(2), 236–243.PubMedCrossRef
109.
Wen, Z., Liu, H., Li, M., Li, B., Gao, W., Shao, Q., Fan, B., Zhao, F., Wang, Q., Xie, Q., Yang, Y., Yu, J., & Qu, X. (2015). Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration. Oncogene, 34(10), 1241–1252.PubMedCrossRef
110.
Fruhbeck, G., et al. (2001). The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. American Journal of Physiology. Endocrinology and Metabolism, 280(6), E827–E847.PubMedCrossRef
111.
Fearon, K. C., Glass, D. J., & Guttridge, D. C. (2012). Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metabolism, 16(2), 153–166.PubMedCrossRef
Metadaten
Titel
Stress, inflammation, and eicosanoids: an emerging perspective
verfasst von
Sujanitha Umamaheswaran
Santosh K. Dasari
Peiying Yang
Susan K. Lutgendorf
Anil K. Sood
Publikationsdatum
09.06.2018
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 2-3/2018
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-018-9741-1

Weitere Artikel der Ausgabe 2-3/2018

Cancer and Metastasis Reviews 2-3/2018 Zur Ausgabe

OriginalPaper

The roles of the COX2/PGE2/EP axis in therapeutic resistance

ReviewPaper

Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them

OriginalPaper

Eicosanoid signaling in carcinogenesis of colorectal cancer

OriginalPaper

Eicosanoids and HB-EGF/EGFR in cancer

OriginalPaper

The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis

OriginalPaper

Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise